Various companies see stock price shifts and analyst rating changes

Various publicly traded companies have seen significant movement in their stock prices and analyst ratings.

Protagonist Therapeutics reached a new 52-week high, with Goldman Sachs raising its rating to “buy” and increasing the price target to $186.00. Similarly, Insight Enterprises hit a 52-week high following a price target increase from JPMorgan Chase & Co. to $160.00. SentinelOne also reached a new 12-month high, despite some mixed analyst feedback, including a target price adjustment by JPMorgan Chase & Co. to $20.00.

In contrast, monday.com saw a reduction in expectations, with Citigroup lowering its price target from $154.00 to $132.00. Essent Group received a price objective increase from Royal Bank of Canada, raising it from $68.00 to $75.00, while maintaining a “sector perform” rating.